DFX Intelligence

Data Factory

Private equityFirmventure with pe activity · probablelower middle market

Omega Fund Management, LLC

Private Equity

Boston, MA

We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.

This is the graph view. The full profile, with its team, deals and sources, is on Private Equity.Open the full profile →

Search this name across graphsid dfx:pe:cb62ce20-2c92-4373-9a14-9c4252e8094a

Data as of Sep 16, 2026 (this record's last observation) from federal regulator filings, firm and issuer disclosures. Page built Sep 20, 2026, 4:01 AM UTC and rebuilt at most every 15 minutes.

Relationships: 178
Dated events: 20
On other graphs: 3
Observed: Sep 13, 2026 to Sep 16, 2026
29 observations

Across DFX

same identity by shared identifier, citation, or a bridge measured by hand

Venture Capitalidentity

Omega Fund Management, LLC

Venture manager · shared crd

Independent Sponsorsidentity

Omega Fund Management, LLC

Capital provider to sponsors · shared crd

RIA / Wealth Managementidentity

OMEGA FUND MANAGEMENT, LLC

Registered adviser · shared crd

Facts

fact = as filed or announced; derived = computed by DFX; estimate = a band, never a point

Funds: 9
PE funds: 9
Vintages: 2015 to 2024
PE GAV, 2024 filing: $694Mgross asset value on Form ADV; never dry powder
Regulatory AUM: $1.6B
Investments: 161
Active investments: 161
Size band: LOWER MIDDLE MARKETderivedproxy: $0.69bn Private Equity Fund GAV on the Form ADV filed 2024-03-30
Latest ADV filing: Mar 30, 2024
Employees (ADV): 24
Website: omegafunds.com

Funds

Fund	Vintage	Lifecycle	ADV type	Form D sold	GAV
Omega Fund Viii, L.P.	2024	Unknown	Private Equity Fund	n/a	$0
Omega Fund VII, L.P.	2022	Early deployment	Private Equity Fund	n/a	$324M
Omega Fund VI, L.P.	2019	Successor fundraising	Private Equity Fund	n/a	$268M
Omega Fund V, LP	2015	Harvest	Private Equity Fund	n/a	$67.8M
Omega Fund I LP	n/a	Wound down	Private Equity Fund	n/a	$3.4M
Omega Fund III GP, LP	n/a	Harvest	Private Equity Fund	n/a	$3.1M
Omega Fund II, LP	n/a	Harvest	Private Equity Fund	n/a	$1.7M
Omega Fund IV LP	n/a	Harvest	Private Equity Fund	n/a	$28.6M
Life Sciences Holdings Spv I Fund, LP	n/a	Harvest	Private Equity Fund	n/a	$189,576

Investments

Company	State	Role	Control	Invested	Exited	Status
Anjarium BioSciences	n/a	unknown	unknown	n/a	n/a	active
Omega Fund IV	n/a	unknown	unknown	n/a	n/a	active
Blincyto	n/a	unknown	unknown	n/a	n/a	active
CropDesign	n/a	unknown	unknown	n/a	n/a	active
Aquarius	n/a	unknown	unknown	n/a	n/a	active
Atea	n/a	unknown	unknown	n/a	n/a	active
DBV Technologies	n/a	unknown	unknown	n/a	n/a	active
Selincro	n/a	unknown	unknown	n/a	n/a	active
Epigenomics	n/a	unknown	unknown	n/a	n/a	active
Cincor	n/a	unknown	unknown	n/a	n/a	active
Mavyret	n/a	unknown	unknown	n/a	n/a	active
Xtuit	n/a	unknown	unknown	n/a	n/a	active
SpineJet	n/a	unknown	unknown	n/a	n/a	active
Arcutis	n/a	unknown	unknown	n/a	n/a	active
Phoqus	n/a	unknown	unknown	n/a	n/a	active
JenaValve Technology Inc	CA	unknown	unknown	n/a	n/a	active
Neuroseal	n/a	unknown	unknown	n/a	n/a	active
Spinevision	n/a	unknown	unknown	n/a	n/a	active
Kestra Medical Technologies	n/a	unknown	unknown	n/a	n/a	active
Median Technologies	n/a	unknown	unknown	n/a	n/a	active
Epi ProColon	n/a	unknown	unknown	n/a	n/a	active
Baxfendy	n/a	unknown	unknown	n/a	n/a	active
Spruce Biosciences, Inc.	CA	unknown	unknown	n/a	n/a	active
Visterra	n/a	unknown	unknown	n/a	n/a	active
Paion	n/a	unknown	unknown	n/a	n/a	active
Encelto	n/a	unknown	unknown	n/a	n/a	active
Intarcia Therapeutics	n/a	unknown	unknown	n/a	n/a	active
Imago BioSciences	n/a	unknown	unknown	n/a	n/a	active
Firazyr	n/a	unknown	unknown	n/a	n/a	active
XII Medical, Inc.	CA	unknown	unknown	n/a	n/a	active

Relationships

showing 80 of 178

Invested in (80)

→ DevelogenCompanyunknown
factDFX's own graph
→ Cidara Therapeutics, Inc.Companyunknown
factDFX's own graph
→ NevisenseCompanyunknown
factDFX's own graph
→ Sosei GroupCompanyunknown
factDFX's own graph
→ PierisCompanyunknown
factDFX's own graph
→ enGeneCompanyunknown
factDFX's own graph
→ Scibase HoldingsCompanyunknown
factDFX's own graph
→ CropDesignCompanyunknown
factDFX's own graph
→ ArcutisCompanyunknown
factDFX's own graph
→ AndrewCompanyunknown
factDFX's own graph
→ Alpine ImmuneCompanyunknown
factDFX's own graph
→ MammaprintCompanyunknown
factDFX's own graph
→ KimmtrakCompanyunknown
factDFX's own graph
→ Ultibro BreezhalerCompanyunknown
factDFX's own graph
→ Nuvation BioCompanyunknown
factDFX's own graph
→ Bioinvent InternationalCompanyunknown
factDFX's own graph
→ Anaconda BiomedCompanyunknown
factDFX's own graph
→ Proteon TherapeuticsCompanyunknown
factDFX's own graph
→ NuzyraCompanyunknown
factDFX's own graph
→ W4Companyunknown
factDFX's own graph
→ XtuitCompanyunknown
factDFX's own graph
→ EthernaCompanyunknown
factDFX's own graph
→ SelincroCompanyunknown
factDFX's own graph
→ Generic LovenoxCompanyunknown
factDFX's own graph
→ Beta BionicsCompanyunknown
factDFX's own graph
→ HybrigenicsCompanyunknown
factDFX's own graph
→ Senti Biosciences, Inc.Companyunknown
factDFX's own graph
→ PhoqusCompanyunknown
factDFX's own graph
→ SpineJetCompanyunknown
factDFX's own graph
→ Sail BiomedicinesCompanyunknown
factDFX's own graph
and 50 more

Dated events

11 bookkeeping events (roster, classification and holdings changes) folded below

Occurred
Aug 24, 2026
Firm news
Valerio Therapeutics announces signing of definitive agreements for the acquisition of Etherna Immunotherapies, building a leading platform in targeted RNA, and €40.25 million PIPE financing from new and existing investors
The subject's own siteobserved 3 days ago
Occurred
Mar 18, 2026
Firm news
Europe’s Biotech Investment Crisis: Otello Stampacchia on The Long Run
The subject's own siteobserved 3 days ago
Occurred
Mar 30, 2024
Person left
Anne-Mari Johanna Paster (Manager) no longer on Schedule A of Omega Fund Management, LLC
Form ADVobserved 6 days ago
Occurred
Oct 1, 2023
Person joined
Francesco Luigi Draetta joined Schedule A of Omega Fund Management, LLC as Manager & Member
Form ADVobserved 6 days ago
Occurred
Jul 1, 2020
Person joined
Alexandra R Pearsall joined Schedule A of Omega Fund Management, LLC as Chief Financial Officer
Form ADVobserved 6 days ago
Occurred
Nov 22, 2019
Person left
Richard Jinkyu Lim (Manager & Member) no longer on Schedule A of Omega Fund Management, LLC
Form ADVobserved 6 days ago
Occurred
Nov 1, 2016
Person joined
Claudio Pier Antonio Nessi joined Schedule A of Omega Fund Management, LLC as Manager & Member
Form ADVobserved 6 days ago
Occurred
Mar 1, 2016
Person joined
Mark Emerson Russell joined Schedule A of Omega Fund Management, LLC as Chief Compliance Officer
Form ADVobserved 6 days ago
Occurred
Feb 15, 2012
Adviser first adv filing
Omega Fund Management, LLC first filed Form ADV in the extract (IA)
Form ADVobserved 6 days ago

Show 11 bookkeeping events

Occurred
Mar 26, 2026
Omega Fund Management, LLC: Private Equity Funds on Form ADV 8 (2024 extract) -> 2 (roster 2026-09-01)
Occurred
Mar 30, 2024
Omega Fund Viii, L.P. first reported on Form ADV by Omega Fund Management, LLC (Private Equity Fund)
Occurred
Mar 31, 2022
Omega Fund VII, L.P. first reported on Form ADV by Omega Fund Management, LLC (Private Equity Fund), GAV $111,255,201
Occurred
Mar 31, 2019
Omega Fund VI, L.P. first reported on Form ADV by Omega Fund Management, LLC (Private Equity Fund)
Occurred
May 8, 2015
Omega Fund V, LP first reported on Form ADV by Omega Fund Management, LLC (Private Equity Fund)
Occurred
Mar 31, 2014
Fund 805-9294258073 no longer reported on Form ADV by Omega Fund Management, LLC
Occurred
Feb 15, 2012
Omega Fund II, LP first reported on Form ADV by Omega Fund Management, LLC (Private Equity Fund), GAV $57,236,000
Occurred
Feb 15, 2012
Omega Fund I LP first reported on Form ADV by Omega Fund Management, LLC (Private Equity Fund), GAV $8,170,000
Occurred
Feb 15, 2012
Life Sciences Holdings Spv I Fund, LP first reported on Form ADV by Omega Fund Management, LLC (Private Equity Fund), GAV $27,424,000
Occurred
Feb 15, 2012
Omega Fund III GP, LP first reported on Form ADV by Omega Fund Management, LLC (Private Equity Fund), GAV $61,229,000
Occurred
Feb 15, 2012
Omega Fund IV LP first reported on Form ADV by Omega Fund Management, LLC (Private Equity Fund), GAV $37,485,000

Who to call

the organisation, the role and the published line, with the filing or website that published it; revealed to signed-in accounts

The firm's published line

Revealable: 1 business phone (Form ADV), 1 office address (Form ADV), 1 website (Form ADV) · as of 2026-09-13

Who to call is the organisation, the person's role and the line they published themselves: a business phone, office address, website or profile link from Form ADV, Form 13F or their own website, with that source named on every value. The counts above are what a reveal returns; a personal email is rarely published, so most reveals are the firm's line. Never data bought from a provider, never anything personal. Reveals by plan

Provenance

Graph: Private Equity
Canonical id: dfx:pe:cb62ce20-2c92-4373-9a14-9c4252e8094a
First observed: Sep 13, 2026
Last observed: Sep 16, 2026 3 days ago
Source families: Federal regulator filings, Firm and issuer disclosures
3 registered feeds stand behind this record; each fact above carries its own dates and, where the publisher serves one, its document.
Resolution: Identity across graphs by shared identifier (CRD, CIK, EIN, ADV fund id, individual CRD) or citation; a name match is shown as a candidate and never merged.

Omega Fund Management, LLC

Private Equity

Boston, MA

We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.

This is the graph view. The full profile, with its team, deals and sources, is on Private Equity.Open the full profile →

Search this name across graphsid dfx:pe:cb62ce20-2c92-4373-9a14-9c4252e8094a

Data as of Sep 16, 2026 (this record's last observation) from federal regulator filings, firm and issuer disclosures. Page built Sep 20, 2026, 4:01 AM UTC and rebuilt at most every 15 minutes.